Abstract 168P
Background
It is important to predict prognosis in patients with advanced gastric cancer receiving chemotherapy. Several studies have reported that Glasgow prognostic score (GPS), which was based on serum albumin (Alb) and C-reactive protein (CRP), was associated with poor prognosis in many cancers. However, it is unclear whether GPS has prognostic value when patients receive Irinotecan, which is a key drug of advanced gastric cancer.
Methods
We conducted a retrospective multicenter study and investigated association between efficacy and GPS in patients who received irinotecan monotherapy between January 2010 and December 2017. All patients had to receive fluoropyrimidine and platinum as prior therapy. GPS was identified that GPS 0 was CRP ≤1.0 mg/dL and Alb ≥3.5 g/dL, GPS 1 was CRP >1.0 mg/dL or Alb <3.5 g/dL, and GPS 2 was CRP >1.0 mg/dL and Alb <3.5 g/dL.
Results
There were 174 patients at 8 centers included in this study. The number of patients with GPS 0/1/2 was 76/56/42, respectively. In GPS 0/1/2 patients, performance status (0-1/2≤), treatment line 2nd/3rd or later, and HER2 status were significantly different among them(p < 0.01). As for safety, there was no significant difference among GPS 0/1/2 patients. In GPS 0/1/2 patients, median PFS were 3.7/2.8/2.0 months (p < 0.01), median OS were 11.9/7.2/6.7 months (p < 0.01), respectively. In multivariate analysis, GPS was associated with shorter PFS (GPS 0 vs 1/0vs 2 : HR 1.180/2.378, 95%C.I. 0.793-1.758/1.405-4.024, p = 0.414/0.001), and shorter OS (GPS 0 vs 1/0vs 2 : HR 1.520/2.529, 95%C.I. 1.002-2.305/1.518-4.213, p = 0.049/<0.001).
Conclusions
In this analysis, GPS might be a predictive and prognostic factor in treatment with irinotecan monotherapy for patients with AGC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yoshito Komatsu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
YO31 - Primary pulmonary sarcoma
Presenter: Khilola Ubaydullaeva
Session: Poster display session
Resources:
Abstract
YO32 - prostatic rhabdomyosarcoma in an adult patient: A case study
Presenter: Muhammad Rafiqul Islam
Session: Poster display session
Resources:
Abstract
YO33 - Hyponatremia – slaying the dragon or chasing a mirage- a Case report
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
YO34 - A rare endocrinological syndrome presenting with weakness in Soft tissue sarcoma - a Case report
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
YO35 - Gefitinib induced movement disorder - a Case report
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
YO36 - A case of BRAF V600E mutated non-small-cell lung cancer with pleomorphic features
Presenter: Reiko Matsuzawa
Session: Poster display session
Resources:
Abstract
YO37 - Intraventricular metastasis as the first presentation of non-small cell lung cancer
Presenter: Siraphong Putraveephong
Session: Poster display session
Resources:
Abstract
YO38 - Cerebral metastases from a thymic malignancy: a case report
Presenter: Marfu'au Nik Eezamuddeen
Session: Poster display session
Resources:
Abstract
YO39 - Primary Follicular Thyroid Carcinoma Metastatic to the Kidney Mimicking Renal Cell Carcinoma: A Case Report
Presenter: Jestoni Aranilla
Session: Poster display session
Resources:
Abstract
YO40 - A Rare Case of Primary Malignant Giant Cell Tumor of Tibia
Presenter: Gowthami Venugopal
Session: Poster display session
Resources:
Abstract